A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo

Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activity in patients with HER2-overexpressing breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Mehdi, Jeddi-Tehrani, Mahmood, Golsaz-Shirazi, Forough, Arjmand, Mohammad, Bahadori, Tannaz, Judaki, Mohammad Ali, Shiravi, Fariba, Zare, Hengameh Ahmadi, Haghighat, Farzaneh Notash, Mobini, Maryam, Amiri, Mohammad Mehdi, Shokri, Fazel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927792/
https://www.ncbi.nlm.nih.gov/pubmed/33679691
http://dx.doi.org/10.3389/fimmu.2020.600883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927792/
https://www.ncbi.nlm.nih.gov/pubmed/33679691
http://dx.doi.org/10.3389/fimmu.2020.600883

Ejemplares similares